Investigational New Drug Application Therapy Targeting Life-Threatening E. coli Infections

"Ua hauʻoli ka hui SNIPR BIOME i kēia koʻikoʻi koʻikoʻi, a ke kakali nei mākou i ka hoʻomaka ʻana i ka hoʻokolohua lapaʻau ma US ma hope o kēia makahiki, e hoʻāʻo ana i kā mākou ʻenehana CRISPR kūʻokoʻa. ʻO SNIPR001 ko mākou waiwai holomua loa, a haʻaheo loa mākou i ka hoʻoikaika ʻana o ka hui i lawe mai iā mākou ma ʻaneʻi," wahi a Kauka Christian Grøndahl, Co-founder & CEO.

Hiki i ka hoʻokolohua lapaʻau ke wehe i ke ala no ke ʻano hou o ka lāʻau precision e koho koho i ka E. coli i nā poʻe maʻi maʻi maʻi me nā maʻi maʻi hematological - ʻo ia nā maʻi maʻi e pili ana i ke koko, ka iwi iwi, a me ka lymph nodes. ʻO kēia mau poʻe maʻi ke piʻi aʻe ka pilikia o nā maʻi koko e hoʻoweliweli i ke ola ma muli o ka maʻi, i ka mālama ʻana i ka chemotherapy a, ʻo ka mea nui, i ka hoʻololi ʻana i ka pathogen mai ka ʻōpū, a ʻo E. coli kekahi o nā mea pāʻani koʻikoʻi i ka hoʻoulu ʻana i ka maʻi.

Manaʻo ʻo SNIPR001 e hoʻopaʻa i ka bacteria E. coli i loko o ka ʻōpū, a ma laila e pale ai i ka unuhi ʻana o kēia mau bacteria i ke kahe koko, ʻoiai e waiho ʻole ana i ka bacteria commensal i loko o ka microbiome o ka mea maʻi. ʻO ka hoʻokokoke ʻana me SNIPR001 ke hoʻohana nei i kahi noi hou o kā mākou ʻenehana CRISPR/Cas ponoʻī e hoʻopau i ka maʻi bacteria E. coli mai ka ʻōpū. Hiki i kēia ala pololei ke hoʻololi i ke ʻano o ka pale ʻana a mālama ʻia ʻana o nā maʻi E. coli, ʻoi aku hoʻi ma ka hale maʻi kanesa.

I kēia lā, ʻaʻohe lāʻau lapaʻau i ʻae ʻia no ka prophylactic therapy ma kēia hoʻonohonoho.

"Ma muli o kā mākou ʻikepili pre-clinical me SNIPR001 ke manaʻoʻiʻo nei mākou he mana nui kā kā mākou ʻenehana i ka hoʻolālā ʻana i nā lāʻau lapaʻau CRISPR o ka lā ʻapōpō e kūʻē i nā maʻi weliweli a me ka hoʻololi ʻana i nā maʻi pili i ka microbiome" wahi a Kauka Milan Zdravkovic, Luna Nui a me ke poʻo. o R&D ma SNIPR Biome. "Me ka piʻi ʻana o ke kū'ē anti-microbial aia kahi makemake nui i nā moho lāʻau lapaʻau hou e mālama i nā bacteria infectious, e like me E. coli, a ke mahalo nei mākou i ka hui pū ʻana me ka hui waiwai ʻole, CARB-X ma SNIPR001".

ʻO SNIPR001 ka mua o nā moho lapaʻau kūpono, e like me ka mea i hōʻike ʻia e Dr. Christian Grøndahl: "Ke kūkulu nei mākou i kahi pipeline ikaika o nā waiwai CRISPR novel a ʻoi aku ma mua o ko mākou makemake i nā maʻi infectious, hui pū me ka MD Anderson Cancer Center ma immuno-oncology, a me Novo Nordisk e pili ana i ka hoʻohana ʻana i nā ʻenehana gen-modulation ma ka microbiome. Hauʻoli mākou e ʻimi i ka mana piha o kā mākou ʻenehana CRISPR i ka wā e hiki mai ana.